This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ACADIA (ACAD) Q1 Earnings Beat, Revenues Fall Shy of Estimates
by Zacks Equity Research
ACADIA's (ACAD) loss narrows in the first quarter of 2021 while its revenues miss the mark. Robust Nuplazid performance drives the top line year over year.
Allogene Therapeutics (ALLO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 47.92% and 56.54%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Allogene (ALLO) CAR T Therapy for Myeloma Gets FDA RMAT Tag
by Zacks Equity Research
FDA grants RMAT designation to Allogene's (ALLO) CAR T cell product candidate for multiple myeloma, ALLO-715. The designation will help accelerate development and review of the candidate.
Allogene Therapeutics (ALLO) Up 3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead's (GILD) CAR T Cell Therapy Yescarta Gets FDA Nod for FL
by Zacks Equity Research
Gilead's (GILD) CAR T-cell therapy gets a boost with the FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.
Allogene (ALLO) Q4 Earnings Top Estimates, Pipeline Advances
by Zacks Equity Research
Allogene (ALLO) reports no revenues for the fourth quarter of 2020.
Allogene's (ALLO) AlloCAR T Therapy ALLO-715 IND Gets FDA Nod
by Zacks Equity Research
The FDA permits Allogene (ALLO) to initiate an early-stage study on its AlloCAR T therapy candidate, ALLO-715, in combination with SpringWorks' nirogacestat in multiple myeloma patients.
Allogene Therapeutics (ALLO) Up 8.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allogene (ALLO) Q3 Earnings Top Estimates, Pipeline Progresses
by Zacks Equity Research
Allogene (ALLO) reports no revenues for the third quarter of 2020.
Allogene Therapeutics (ALLO) Down 9.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allogene's (ALLO) Q2 Loss Widens Y/Y, Pipeline Progresses
by Zacks Equity Research
Allogene (ALLO) reports no revenues for the second quarter of 2020.
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ALLO) Outperforming Other Medical Stocks This Year?
Has Allogene Therapeutics (ALLO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ALLO) Outperforming Other Medical Stocks This Year?
Why Is Allogene Therapeutics (ALLO) Up 40.6% Since Last Earnings Report?
by Zacks Equity Research
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Moving Average Crossover Alert: Allogene Therapeutics
by Zacks Equity Research
Allogene Therapeutics, Inc. (ALLO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Is Allogene Therapeutics (ALLO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ALLO) Outperforming Other Medical Stocks This Year?
Implied Volatility Surging for Allogene (ALLO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Allogene (ALLO) stock based on the movements in the options market lately.
Allogene Therapeutics (ALLO) in Focus: Stock Moves 6.6% Higher
by Zacks Equity Research
Allogene Therapeutics (ALLO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Will Allogene Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Allogene Therapeutics
How Allogene (ALLO) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Allogene (ALLO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Allogene's (ALLO) Q1 Loss Widens Y/Y, Pipeline Progresses
by Zacks Equity Research
Allogene (ALLO) reports no revenues for the first quarter of 2020.
Drug/Biotech Stock Q1 Earnings Due on May 6: ZTS, ALXN & More
by Kinjel Shah
Let us take a look at five drug/biotech companies due to release their first-quarter financial results on May 6.
5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
Why Earnings Season Could Be Great for Allogene Therapeutics (ALLO)
by Zacks Equity Research
Allogene Therapeutics (ALLO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season
Moderna (MRNA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Progress of its pipeline candidates, especially coronavirus vaccine, is likely to have increased Moderna's (MRNA) operating expenses in the first quarter.